ArticleMolecular cancer therapeutics2013
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Haibo Lu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
43 papers cite it
this papercites it